FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Advisors Asked if Retinal Prosthesis is Safe, Effective

[ Price : $8.95]

FDA asks members of its Ophthalmic Devices Panel whether a retinal prosthesis is likely to be safe and effective in inducing visua...

FDA Approves REMS for Mycophenolate Drugs

[ Price : $8.95]

FDA approves a REMS including a pregnancy registry for all mycophenolate-containing drugs.

Device-related Key Issues Under FDASIA: Blog

[ Price : $8.95]

A Hyman Phelps & McNamara blog posting summarizes key provisions CDRH is working on after the passage of the FDA Safety and Innova...

Pfizer Wants Generic Oxecta ANDA Restrictions

[ Price : $8.95]

Pfizer asks FDA to require applicants for generic Oxecta to use the same inactive ingredients that contribute to its safety profil...

Comments Extended on Antimicrobial New Animal Drugs

[ Price : $8.95]

Federal Register Advance notice of proposed rulemaking: FDA extends the comment period on potential changes to its regulations for...

FDA Commissioner Delegated Authority on Clinical Trial Info

[ Price : $8.95]

Federal Register Notice: The HHS Secretary delegates authority to the FDA commissioner to determine that any clinical trial inform...

Panel to Discuss Janssen NDA for TB

[ Price : $8.95]

Federal Register Notice: FDAs Anti-Infective Drugs Advisory Committee will meet 11/28 to discuss a Janssen Therapeutics NDA for tr...

Sucampo/Takeda Get Priority Review for Constipation Treatment

[ Price : $8.95]

FDA grants priority review for a Sucampo/Takeda Pharmaceuticals sNDA for Amitiza (lubiprostone) for treating opioid-induced consti...

CDRH Deputy Director Maisel Pleads Guilty to Prostitution Charges

[ Price : $8.95]

CDRH deputy director for science and chief scientist William H. Maisel pleads guilty in Maryland district court to charges of soli...

Vantas Caregiver Brochure Omits Risk Informatio: OPDP

[ Price : $8.95]

CDERs Office of Prescription Drug Promotion says that an Endo caregiver brochure downplays significant risks associated with Vanta...